This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
H. Lundbeck A/S
Drug Names(s): Lu AA37096
Description: Lu AA37096 has been discovered based on findings with the mechanism of action of escitalopram (Cipralex), a serotonin reuptake inhibitor, but incorporates effects on a number of additional targets in the brain. Lu AA37096 has shown efficacy in animal models of mood disorders as well as in pain models.
Lundbeck has not released specifics about the mechanism of action of Lu AA37096. Escitalopram binds to two sites on the serotonin reuptake transporter. In addition to binding to the primary binding site, like SSRIs, which blocks reuptake of serotonin, escitalopram also binds to a secondary site. This induces a conformational change, that leads to tighter binding of escitalopram at the primary site.
Lu AA37096 News
Additional information available to subscribers only: